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Abstract
Purpose This study aimed to establish the maximum
tolerated dose of concurrent chemoradiotherapy (cCRT)
with conventional administration of the docetaxel (D) plus
cisplatin (P) (conv-DP) regimen.
Methods Patients (aged B70 years) with unresectable dry
stage III non-small-cell lung cancer (NSCLC) and having
performance status 0 or 1 and adequate organ function
were eligible. They received radiotherapy (60 Gy in 30
fractions) once daily starting on day 2. Concurrent P (day
1; 60 mg/m
2 at Levels 1–3, 80 mg/m
2 at Level 4) and D
(day 1; 30 mg/m
2 at Level 1, 40 mg/m
2 at Level 2, 50 mg/m
2
at Levels 3–4) were administered every 4 weeks for 2–4
courses.
Results Eighteen patients were enrolled (stage IIIA/IIIB,
5/13 patients). Three cases of dose-limiting toxicity were
observed in this study, although another 3 cases were added
at Levels 2 and 3. Radiotherapy was completed in 15
patients. Seventeen patients received more than 2 courses
of chemotherapy. Neither Grade 3/4 esophagitis nor severe
hematological events were observed at Levels 1–4.
However, dose escalation to Level 5 (P [80 mg/m
2], D
[60 mg/m
2]) was stopped because the Level 5 dose was the
recommended dose (RD) of chemotherapy alone for stage
IIIB/IV NSCLC in Japan. Therefore, the RD was deter-
mined as D50/P80 mg/m
2 in this cCRT. The objective
response rate was 89 %, and the median survival time was
23.6 months.
Conclusions cCRT with non-split DP was a tolerable and
effective regimen, and RD was 50/80 mg/m
2 every
4 weeks.
Keywords Non-small-cell lung cancer  Locally
advanced  Concurrent chemoradiation  Cisplatin 
Docetaxel
Introduction
Approximately 30 % of patients with non-small-cell
lung cancer have unresectable locally advanced disease
(LA-NSCLC) at diagnosis. Before the 1980s, thoracic
radiotherapy (TRT) was the standard treatment for these
patients. In the 1980s, several studies demonstrated that 2
cycles of chemotherapy followed by radiation improved
the median survival time by approximately 3 months and
5-year survival by 3–10 % compared with TRT alone
[1, 2]. In the 1990s, studies from the United States [3],
Japan [4], and elsewhere demonstrated that concurrent
administration of 2 cycles of chemotherapy with TRT
improved the median survival time by additional 3 months
and 5-year survival by an additional 5 % compared with
sequential chemoradiotherapy. Therefore, treatment rec-
ommended for LA-NSCLC patients who have a good
performance status (PS) is concurrent chemoradiotherapy
(cCRT). In the 1990s, platinum-based third-generation
Presented in part at the Forty-ﬁfth Annual Meeting of the American
Society of Clinical Oncology, Orlando, FL, USA, May 29–June 2,
2009.
N. Hida (&)  H. Okamoto  Y. Misumi  A. Sato  M. Ishii 
F. Kashizaki  T. Shimokawa  K. Watanabe
Department of Respiratory Medicine and Medical Oncology,
Yokohama Municipal Citizen’s Hospital, 56 Okazawa-cho,
Hodogaya-Ku, Yokohama, Kanagawa 240-8555, Japan
e-mail: na00-hida@city.yokohama.jp
T. Shimizu
Department of Radiology, Yokohama Municipal Citizen’s
Hospital, 56 Okazawa-cho, Hodogaya-Ku, Yokohama,
Kanagawa 240-8555, Japan
123
Cancer Chemother Pharmacol (2012) 69:1625–1631
DOI 10.1007/s00280-012-1871-5chemotherapy (i.e., paclitaxel, vinorelbine, and docetaxel)
was shown to be superior to second-generation chemo-
therapy (i.e., etoposide, vindesine, and mitomycin) in
treating metastatic NSCLC [5–7]. However, full-dose
chemotherapy with cCRT using a platinum-based third-
generation doublet is considered to have unacceptable
toxicity. Therefore, for both reduction in toxicity and
enhancement of the radiosensitizing effect, weekly split
chemotherapy has often been used in chemoradiotherapy
with a platinum-based third-generation doublet. In the
curative setting, distant metastasis control is one of the
most important factors. Furuse et al. [4] reported that
the distant relapse rate was 64 % among patients treated
with mitomycin, vindesine, and cisplatin as cCRT. To
prevent distant metastatic relapse, it is necessary to
enhance the effect of chemotherapy. In metastatic NSCLC,
chemotherapy with cisplatin and docetaxel (DP) is one of
the most effective regimens [7]. Thus, to maximize che-
motherapeutic effectiveness, we used DP as concurrent
chemotherapy in both conventional and non-split admin-
istration. This phase I study aimed to establish the maxi-
mum tolerated dose (MTD) of chemoradiotherapy with the
conventional administration of DP therapy.
Patients and methods
Eligibility criteria
Staging for enrollment criteria was performed according to
the lung cancer staging system of the International Union
against Cancer [8]. Staging procedures included chest
radiograph, computed tomography (CT) scan of the chest,
CT scan or magnetic resonance imaging (MRI) of the brain,
CT scan or ultrasound of the abdomen, and isotope bone
scanning. Lymph nodal involvement was mainly based on
size criteria indicated in the chest CT scan. The mediastinal
lymph node beyond 10 mm in the short axis diameter was
consideredasinvolvementnode.Patientswithhistologically
or cytologically documented LA-NSCLC were enrolled in
this study. Other eligibility criteria included the following:
(1) unresectable clinical stage IIIA/IIIB on examination
2 weeks before enrollment; (2) age B70 years; (3) Eastern
Cooperative Oncology Group (ECOG) PS 0 or 1; (4) mea-
surable or assessable tumors; (5) adequate bone marrow
function (white blood cell count C4,000/mL and B12,000,
plateletcountC10 9 10
4/mL,andhemoglobinlevelC10 g/
dL), renal function (serum creatinine (Cr) level B1.5 mg/dL
orcreatinineclearance(Ccr)C60 mL/min),hepaticfunction
(bilirubin level B1.5 times upper limit of normal and
aspartate aminotransferase (AST) B2 times upper limit of
normal), and pulmonary function (arterial blood oxygen
(PaO2) C70 mmHg); (6) life expectancy [8 weeks;
(7)predictedareaoftheradiationﬁeldwaslessthanhalfof1
lung; (8) absence of previous chemotherapy or TRT; and (9)
no previous or concurrent malignancy. Exclusion criteria
included interstitial pneumonitis or pulmonary ﬁbrosis,
pleural or pericardial effusion, severe superior vena cava
syndromerequiringemergentradiotherapy,activeinfection,
poorly controlled diabetes mellitus, uncontrollable cardiac
arrhythmia orhypertension,andacutemyocardial infarction
within 3 months before study enrollment. All patients
gave written informed consent according to institutional
guidelines. This protocol was approved by the Ethical
Committee of Japan Clinical Oncology Group (JCOG) and
our institute.
Treatment plan
In every case, CT results were used to guide radiotherapy.
Moreover, the more accurate three-dimensional conformal
radiotherapy (3D-CT) simulation technique was used in 12
of 18 cases since May 2001 in our institution. The initial 6
cases were radiated by the conventional radiation method
but not by the 3D technique. Radiotherapy was adminis-
tered using an angled ﬁeld technique modulated on the
volume and location of the disease so as to include 100 %
of the target volume in the isodose, with a maximum dose
to the spine of 50 Gy.
The initial opposing anterior–posterior treatment ﬁelds
encompassed the primary tumor, bilateral mediastinal
lymph nodes, and ipsilateral hilar nodes. The supraclavic-
ular nodes were included within the ﬁeld in case of avail-
ability of clinical evidence of their involvement. The gross
tumor volume was the clinical target volume (CTV), and
the planning target volume was CTV plus the surrounding
1.5-cm margin. The total referred dose was 60 Gy with a
classical fractionation of 2 Gy/day (consecutive 5 days/
week). Concurrent radiotherapy began on the day after
chemotherapy started (day 2). The maximum duration of
radiotherapy was 55 days. Lung parenchyma correctional
factors and linear accelerator with photon regimen (nomi-
nal energy 6–10 MV) were used in all cases.
On days 1 and 29, docetaxel was intravenously admin-
istered for 1 h followed by a 2-h infusion of cisplatin.
Concurrent treatment with antiemetics, hydration, antibi-
otics, sedatives, cortisone, and gastric protectors was per-
mitted. Up to 2 courses of consolidation chemotherapy
with the same regimen (cisplatin and docetaxel every
28 days) was permitted after 2 courses of cCRT.
During chemoradiation, if the white blood cell (WBC)
count was\1,000/mm
3 or absolute neutrophil count (ANC)
was\500/mm
3, radiotherapy was stopped and daily gran-
ulocyte colony-stimulating factor (G-CSF) was subcuta-
neously administered until the WBC count increased to
2,000/mm
3. If the platelet count was \5 9 10
4/mm
3 or
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apy was stopped. If the WBC count was [2,000/mm
3,
ANC count was [1,000/mm
3, platelet count was
[5 9 10
4/mm
3, or PaO2 was decreased by \10 mmHg
from baseline, radiotherapy was restarted. Radiotherapy
and concomitant use of G-CSF was contraindicated. If
esophagitis of Grade 3 or higher occurred, radiotherapy
was stopped until recovery to Grade 2 or lower. If hema-
tological toxicities rated as Grade 4 occurred during the
ﬁrst course of chemotherapy, the dose of docetaxel was
reduced by 25 %.
When the second course of chemotherapy was started,
each patient was required to meet the following criteria:
WBC count[3,000/mm
3, platelet count[7.5 9 10
4/mm
3,
AST and/or alanine aminotransferase (ALT) B2.5 9 nor-
mal upper limit, PS 0–2, and Cr level B1.5 mg/dL. If the
aforementioned criteria were not met, only radiotherapy
was started. When the criteria were met, chemotherapy was
started as soon as possible. If the second course was
delayed 2 weeks or more because of toxicity, further che-
motherapy was discontinued and only radiotherapy was
used. If Cr was B1.5 mg/dL and Ccr was C60 mL/min on
the day chemotherapy was started, the full dose of cisplatin
was administered. If Cr was B1.5 mg/dL and Ccr was
within the range of 40–60 mL/min, a 75 % dose of cis-
platin was administered. If Ccr was\40 mL/min, chemo-
therapy was stopped. During chemotherapy alone, the dose
modiﬁcation schedule was almost the same as that during
the chemoradiation period. If the same toxicities were
observed after dose reduction, the protocol treatment was
terminated.
Treatment evaluation
Tumor response and toxicity were evaluated according to
World Health Organization response criteria [9] and Japan
Clinical Oncology Group (JCOG) toxicity criteria [10],
respectively. Extramural review was not performed. Dur-
ing the treatment, complete blood cell count and routine
blood chemistry were examined two times a week and
PaO2 and chest radiographs were examined at least once a
week until the patient had apparently recovered from all
acute toxic effects. Dose-limiting toxicity (DLT) was
evaluated by administering 2 courses of chemotherapy to
each patient. The objective response rate (ORR) was
deﬁned as the proportion of patients (out of all eligible
patients) with complete response (CR) or partial response
(PR). Overall survival (OS) was measured from the date
of patient registration to the date of death from any cause.
If a patient was alive at the ﬁnal follow-up survey, OS
was censored at the last contact date. The estimates of
survival distribution were calculated using the Kaplan–
Meier method.
Study design
This study was a phase I dose escalation study conducted at
a single institution (Yokohama Municipal Citizens Hospi-
tal, Yokohama, Japan) and was designed to deﬁne MTD of
both cisplatin and docetaxel when combined with concur-
rent TRT. The ﬁrst dose level consisted of cisplatin 60 mg/
m
2 and docetaxel 30 mg/m
2. The dose escalation plan and
study procedure is shown in Fig. 1. Dose-limiting toxicity
was deﬁned as Grade 3 or Grade 4 non-hematological
toxicity excluding nausea or vomiting and alopecia, Grade
4 neutropenia lasting 4 days or more, Grade 4 febrile
neutropenia, Grade 4 thrombocytopenia, Grade 3 or higher
esophagitis, or acute interstitial pneumonia (any grade)
during 2 courses of chemotherapy. Patients who could not
meet the criteria for the next course of chemotherapy after
more than 6 weeks had passed from the time of the last
treatment were considered to have developed DLT. If 1 or
2 instances of DLT were observed among 3 patients, 3
additional patients were to be treated at the same dose
level. Dose escalation continued if DLT was observed in no
more than 3 of 6 patients. If 3 of 3 patients or at least 4 of 6
patients showed DLT at a given dose level, then that level
Level 1
Cisplatin 60mg/m2
Docetaxel 30mg/m2
N=3
No DLTs were observed
Level 2
Cisplatin 60mg/m2
Docetaxel 40mg/m2
N=3
Gr4 pneumonitis (DLT)
Three patients were added
in level 2. (total N=6)
No other DLTs were observed
Total DLTs were 1/6
Level 3
Cisplatin 60mg/m2
Docetaxel 50mg/m2
N=3
Gr4 cerebral infarction(DLT)
Three patients were added
in level 3. (total N=6)
Gr3 arrhythmia, hypotension 
Total DLTs were 2/6
Level 4
Cisplatin 80mg/m2
Docetaxel 50mg/m2
N=3
No DLTs were observed
+
+
Level 5
Cisplatin 80mg/m2
Docetaxel 60mg/m2
Not done
Fig. 1 Dose escalation and study procedure
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level to be RD.
Results
Patient characteristics
Between July 1999 and May 2006, 18 patients were
enrolled in this trial. Median age was 60 years (range,
43–70 years) and PS of 1 was observed in 14 patients.
Clinical staging identiﬁed 5 patients as stage IIIA and 13
patients as stage IIIB. Histology was conﬁrmed as follows:
adenocarcinoma in 9 patients (50 %), squamous cell car-
cinoma in 7 patients (39 %), and large cell carcinoma in 2
patients (11 %) (Table 1).
Dose escalation procedure
The procedures followed in this phase I study are shown in
Fig. 1. No DLTs were observed at Level 1. At Level 2
(cisplatin 60 mg/m
2 and docetaxel 40 mg/m
2), 1 of 6
patients showed DLT. The patient was a 67-year-old man
who was an ex-smoker (100 packs/year). The comorbidity
of this patient was cardiac dysfunction due to mitral valve
regurgitation. Hypoxia and interstitial shadow developed at
day 29 after the initiation of the protocol treatment. Despite
steroid pulse therapy following immediate discontinuation
of chemoradiotherapy, this patient died of respiratory
failure and progression of lung cancer on day 83. This case
was considered to be Grade 4 pneumonitis (unrecovered).
Although additional 3 patients were added at Level 2, no
other DLTs were observed; thus, the dose was escalated to
Level 3 (cisplatin 60 mg/m
2 and docetaxel 50 mg/m
2).
However, one of the ﬁrst 3 patients added at Level 3 had
DLT. This 58-year-old woman developed Grade 4 cerebral
infarction. The patient developed right hemiparesis and
aphasia at 3 weeks after the ﬁrst course of chemotherapy
and 30 Gy of irradiation. She recovered from hemiparesis
but mild aphasia remained. After the patient recovered
from the severe toxicity, thoracic irradiation was continued
up to 60 Gy. We considered this event to be a Grade 4
adverse event and judged it to represent DLT. Although
additional 3 patients were added at Level 3, 1 patient
developed Grade 3 atrial ﬁbrillation and hypotension
5 days after the second course of chemotherapy. This
patient completely recovered without complications within
a few days. Because only 2 of 6 patients had DLTs at Level
3, the dose was escalated to Level 4 (cisplatin 80 mg/m
2
and docetaxel 50 mg/m
2); at this level, no DLTs were
encountered. However, dose escalation to Level 5 (cis-
platin 80 mg/m
2 and docetaxel 60 mg/m
2) was stopped
because the Level 5 dose was the recommended dose of
chemotherapy alone for stage IIIB/IV NSCLC in Japan.
This decision was approved by the JCOG Data and Safety
Monitoring Committee. Thus, although MTD was not
obtained in this study, the recommended dose was con-
sidered to be cisplatin 80 mg/m
2 and docetaxel 50 mg/m
2.
Seventeen patients received more than 2 courses of
chemotherapy. Median interval by third course was
28 days, and no dose reductions were observed in all
courses. Due to disease progression, one patient received
only one course of chemotherapy. Eight patients received
additional 2 courses of consolidation chemotherapy
(Table 2). Radiotherapy (60 Gy) was completed in 15
patients (Table 3).
Toxicities
Therapeutic toxicities are summarized in Table 4. Grade 3
leukocytopenia, neutrocytopenia, and thrombocytopenia
were observed in 5 patients (28 %), 4 patients (22 %), and
1 patient (6 %), respectively. No Grade 4 hematological
event was observed. No Grade 3 or higher esophagitis or
other gastrointestinal toxicities were observed. Other
severe (Grade 3 and higher) toxicities were determined to
Table 1 Patient characteristics
No. of patients 18
Gender
Male 13
Female 5
Age
Median (Range) 60 (43–70)
Histology
Squamous cell carcinoma 7
Adenocarcinoma 9
Large cell carcinoma 2
Stage
IIIA 5
IIIB 13
ECOG-PS
04
11 4
ECOG, eastern cooperative oncology group; PS, performance status
Table 2 Chemotherapy interval and dose reduction
Chemotherapy
course
N Days Dose
reduction
1–2 course 17 27–35 (median 28) –
2–3 course 9 28–32 (median 28) 0
3–4 course 8 28–38 (median 29) 0
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toxicities (i.e., radiation pneumonitis, prolonged esopha-
gitis, or spinal cord toxicities) were observed in all long-
term survivors.
Responses, recurrence pattern, and survival
All 18 patients enrolled were considered for response on an
intent-to-treat basis. Overall, 16 patients showed an objec-
tive response to treatment (no CRs), yielding an 89 %
response rate. The pattern of initial recurrence is shown in
Table 5.Distantrelapse(67 %)washigherthanlocoregional
relapse (33 %). At the time of this report, 14 deaths had
occurred. The median follow-up for overall and surviving
patients was 19.8 (range, 2.8–69.7) and 42.9 (range,
19.9–69.7) months, respectively. The median progression-
free survival was 8.4 months. The median survival time was
23.6 months,withanestimated2-yearsurvivalrateof43 %.
Discussion
We evaluated the use of simultaneous irradiation with
coadministration of a third-generation agent doublet to
enhance the effect of chemotherapy. Speciﬁcally, our phase
I study explored the safety and optimal dose of conven-
tional and non-split administration of cisplatin and doce-
taxel therapy as cCRT. The optimal regimen, dosage, and
administration of a third agent for LA-NSCLC are con-
troversial. Combination chemotherapy using a reduced or
fractionated dose of platinum plus third-generation agents
has been administered to reduce toxicity in many clinical
trials [11, 12]. However, in our study, the chemotherapy
dose was escalated to almost the recommended full dose of
chemotherapy administered alone for metastatic NSCLC in
Japan. The dose was escalated to cisplatin 80 mg/m
2 and
docetaxel 50 mg/m
2 (Level 4), which is close to the full
dose. The protocol speciﬁed further escalation to the rec-
ommended full dose of cisplatin 80 mg/m
2 and docetaxel
60 mg/m
2 (Level 5). However, no new anticancer drug has
been used concomitantly with cisplatin-based chemother-
apy and radiotherapy at a full dose, and Level 5 was the
recommended dose of chemotherapy alone for stage IIIB/
IV NSCLC in Japan. Thus, chemotherapy at Level 5 was
not conducted, as agreed by the JCOG Data and Safety
Monitoring Committee. Therefore, a dose of cisplatin
80 mg/m
2 and docetaxel 50 mg/m
2 (Level 4) is recom-
mended for future study.
A treatment strategy with chemoradiotherapy aimed at a
complete cure of LA-NSCLC should include both local and
distant disease control. Local control improves by simul-
taneous radiotherapy. Docetaxel enhances the cytotoxic
effects of radiotherapy in vitro [13, 14], with radiation
enhancement being superior to that observed with paclit-
axel [15]. The combined administration of cisplatin and
irradiation improved survival and decreased the local
failure rate, although the addition of relatively low doses of
cisplatin did not decrease the distant failure rate [16–18].
To enhance local tumor control without increasing
toxicity, we could use the 3D-CRT technique in the study.
Although there are only a few small studies of radiation
dose escalation using 3D-CRT [19–21], this technique is
expected to reduce radiation-related toxicity. Large-scale
trials are necessary to evaluate whether better tumor con-
trol because of the higher doses and reduced toxicity is
Table 3 Radiotherapy delivery
Level N RT dose (Gy) With RT delay
1 3 60, 60, 60 1 (3 days)
2 6 60, 36
a,6 0 0
60, 60, 56
b
3 6 60, 60
c,6 0
60, 60, 60
d 2
4 3 60, 60, 60 0
No/N, number; RT, radiation therapy; DLT, dose-limiting toxicity
a Died with Gr4 pneumonitis 58 days after 2nd course of chemo-
therapy (DLT)
b Gr2 infection
c Gr4 cerebral infarction
d Gr3 Atrial ﬁbrillation and hypotension
Table 4 Toxicities (worst of any course)
Level Hematological toxicities Hb PLT Gastrointestinal toxicities
N WBC Grade ANC N and V Grade diarrhea Esophagitis
2 3 4 2342 3 2 3 4 C2 C22 3 o r 4
1 3 1 0 0 1002 0 0 0 0 0 0 00
2 6 2 1 0 5101 0 0 0 0 0 0 10
3 6 2 3 0 3203 0 0 1 0 2 1 10
4 3 0 1 0 0100 0 0 0 0 2 0 20
N, number; WBC, white blood cell; ANC, absolute neutrophil count; Hb, Hemoglobin; PLT, platelet, N and V, nausea and vomitting
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expected because higher doses of radiation can be deliv-
ered to the tumor while decreasing the dose of radiation
administered to surrounding healthy tissues.
Distant disease control mainly depends on the strength
of chemotherapy. In chemoradiotherapy, divided doses of
many third-generation anticancer drugs have been used to
reduce toxicity. Consequently, although toxicity is clearly
reduced, the antitumor effect throughout the entire body
may be decreased. Docetaxel is one of the most effective
antitumor agents; therefore, we expected that conventional
and non-split administration of docetaxel would provide
improved efﬁcacy for the entire body than split adminis-
tration. However, of the 12 patients who had disease
relapse in this study, the initial site of recurrence was
distant in 8 patients and local in 4 patients. These results
were unexpected; however, patients treated with low-dose
chemotherapy (Levels 1–3) were included in this group.
Further studies are required to investigate this issue.
Prophylactic cranial irradiation (PCI) in LA-NSCLC has
been discussed because the brain is the ﬁrst site of distant
recurrence in many treated patients. In a comparative study
of additional PCI after chemoradiotherapy in LA-NSCLC
patients, Gore et al. and Sum et al. found that PCI affected
the time to brain metastasis and quality of life but did
not improve survival [22, 23]. Dimitropoulos et al. [24]
reported the maximum beneﬁt of PCI may bestow on
younger smokers, which is not mainly population of
NSCLC. The usefulness of PCI in LA-NSCLC remains
controversial. In our study, 8 of 18 patients were treated
with consolidation chemotherapy, although there has been
no deﬁnitive evidence for using consolidation chemother-
apy after chemoradiation therapy. Additional consolida-
tions consisting of docetaxel [25] or geﬁtinib [26] after the
induction of cisplatin plus etoposide reported no effect on
survival. Although consolidation chemotherapy may have a
possible effect in reducing distance metastasis, its role after
induction chemoradiotherapy remains controversial [27].
Grade 3 or higher non-hematological toxicity occurred
in 3 patients. One patient had Grade 4 pneumonitis during
chemoradiotherapy at Level 2. This patient had cardiac
dysfunction, and the irradiation ﬁeld was relatively exten-
sive, although covering less than half of 1 lung. No other
cases of serious pneumonitis were observed. The other 2
adverse events were cerebral infarction associated with
mild paralysis and transient atrial ﬁbrillation associated
with hypotension. However, these adverse events were
incidental. Overall toxicity was generally mild; speciﬁ-
cally, no Grade 3 or higher esophagitis was found.
It is difﬁcult to evaluate efﬁcacy because this study was
conducted as a phase I dose escalation trial. However, the
overall response rate (PR ? CR) was 89 %, median pro-
gression-free survival was 8.4 months, median survival
time was 23.6 months, and the 2-year survival rate was
43 %, that is, the overall outcomes were promising com-
pared with the results of recent randomized phase III trials.
Studies OSCLG0007 [11] and WJTOG0105 [12] were
randomized controlled trials of cCRT for LA-NSCLC
using platinum and a third-generation doublet. These
studies reported that the median OS of the experimental
arm was 19.8–26.8 months. Ohyanagi et al. [28] reported
the results of a phase II trial of cisplatin (60 mg/m
2, day 1)
and S-1 (orally at 40 mg/m
2 daily, days 1–14) administered
as conventional (non-fractionated) chemotherapy with
concurrent radiotherapy. These authors reported an excel-
lent median survival of 33.1 months and a distant failure
rate of 50 %. Based on our promising phase I trial, a ran-
domized comparative study of cisplatin plus docetaxel or
TS-1 with concurrent radiotherapy is being conducted by
the Thoracic Research Oncology Group (TORG) of Japan.
In conclusion, cCRT with non-split DP therapy seemed
to be a tolerable and effective regimen for NSCLC patients
in our phase I study. RD for DP was 50 and 80 mg/m
2
every 4 weeks. The use of cCRT with near full dose, non-
split administration of cisplatin and a third-generation drug
appears to be a promising strategy. A further trial is being
planned to evaluate the efﬁcacy and toxicity of this mul-
timodal therapy.
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